Ionis Pharmaceuticals (IONS) Non-Current Assets (2009 - 2026)

Ionis Pharmaceuticals' Non-Current Assets history runs 18 years deep, the most recent figure standing at $513.0 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 30.2% year-over-year to $513.0 million in Q1 2026; TTM through Mar 2026 was $2.0 billion, a 30.66% increase from a year earlier, with the FY2025 full-year figure at $533.2 million, up 39.08% from the prior year.
• Non-Current Assets eased to $513.0 million in Q1 2026 per IONS's latest filing, from $533.2 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $533.2 million in Q4 2025 and bottomed at $265.0 million in Q2 2022.
• The 5-year median for Non-Current Assets is $354.4 million (2023), against an average of $373.5 million.
• Across the five-year window, Non-Current Assets advanced 1.65% in 2024 and surged 39.99% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $331.2 million in 2022, then advanced by 5.14% to $348.2 million in 2023, then increased by 10.1% to $383.4 million in 2024, then surged by 39.08% to $533.2 million in 2025, then fell by 3.78% to $513.0 million in 2026.
• Per Business Quant, the three latest IONS Non-Current Assets figures stand at $513.0 million (Q1 2026), $533.2 million (Q4 2025), and $514.1 million (Q3 2025).